<DOC>
	<DOC>NCT01123785</DOC>
	<brief_summary>The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.</brief_summary>
	<brief_title>A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>1. Subject has the diagnosis of ocular hypertension (OHT) or primary openangle glaucoma (POAG). 2. Aged 18 to 75 years. 3. Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg. 1. No significant visual field loss or any new field loss within the past year. 2. Cuptodisc ratio ≥0.8 3. Central corneal thickness &lt;500 µm or &gt;600 µm 4. History of adult asthma or chronic obstructive pulmonary disease 5. A recent (acute) or chronic medical condition that might obfuscate the Subject's study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>adenosine agonist</keyword>
	<keyword>eye drop</keyword>
	<keyword>primary open angle glaucoma</keyword>
</DOC>